FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004703251> ?p ?o ?g. }

• W2004703251 endingPage "1135" @default.
• W2004703251 startingPage "1130" @default.
• W2004703251 abstract "A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). S-1 was administered orally at 80 mg m-2 day-1 from day 1 to 14 of a 28-day cycle and CPT-11 was given intravenously on day 1 and 8 at an initial dose of 70 mg m-2 day-1, stepping up to 100 mg m-2. The treatment was repeated every 4 weeks, unless disease progression was observed. In the phase I portion, the MTD of CPT-11 was presumed to be 100 mg m-2, because 66.6% of patients (two of three) developed DLTs. All three patients at the initial RD of CPT-11 (90 mg m-2) experienced grade 4 haematological or grade 3 nonhaematological toxicities at second course, followed by the dose reduction of CPT-11 from the third course. Considering safety and the ability to continue treatment, the final RD was determined to be 80 mg m-2. In the phase II portion, 42 patients including seven patients in the final RD phase I portion were evaluated. The median treatment course was five (range: 1-13). The incidences of severe (grade 3-4) haematological and nonhaematological toxicities were 19 and 10%, respectively, but all were manageable. The RR was 62% (26 of 42, 95% confidence interval: 47.2-76.6%), and the median survival time was 444 days. Our phase I/II trial showed S-1 combined with CPT-11 is effective for AGC and is well tolerated, with acceptable toxicity." @default.
• W2004703251 created "2016-06-24" @default.
• W2004703251 creator A5000738181 @default.
• W2004703251 creator A5008014743 @default.
• W2004703251 creator A5018138745 @default.
• W2004703251 creator A5026785555 @default.
• W2004703251 creator A5034002948 @default.
• W2004703251 creator A5054141760 @default.
• W2004703251 creator A5065402521 @default.
• W2004703251 creator A5072306746 @default.
• W2004703251 date "2006-03-28" @default.
• W2004703251 modified "2023-10-16" @default.
• W2004703251 title "Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer" @default.
• W2004703251 cites W1843791750 @default.
• W2004703251 cites W1848862702 @default.
• W2004703251 cites W1858848802 @default.
• W2004703251 cites W1927999720 @default.
• W2004703251 cites W1928747779 @default.
• W2004703251 cites W1944693814 @default.
• W2004703251 cites W1976651872 @default.
• W2004703251 cites W1978144914 @default.
• W2004703251 cites W1992408996 @default.
• W2004703251 cites W2000330957 @default.
• W2004703251 cites W200233776 @default.
• W2004703251 cites W2008575122 @default.
• W2004703251 cites W2013537137 @default.
• W2004703251 cites W2018619890 @default.
• W2004703251 cites W2054459150 @default.
• W2004703251 cites W2068225833 @default.
• W2004703251 cites W2077902459 @default.
• W2004703251 cites W2096139576 @default.
• W2004703251 cites W2104264282 @default.
• W2004703251 cites W2106269708 @default.
• W2004703251 cites W2119071284 @default.
• W2004703251 cites W2127191258 @default.
• W2004703251 cites W2128447158 @default.
• W2004703251 cites W2130522735 @default.
• W2004703251 cites W2143863553 @default.
• W2004703251 cites W2150200280 @default.
• W2004703251 cites W2152805228 @default.
• W2004703251 cites W2222330038 @default.
• W2004703251 cites W2314927739 @default.
• W2004703251 cites W2332894026 @default.
• W2004703251 cites W2528428498 @default.
• W2004703251 cites W78979634 @default.
• W2004703251 doi "https://doi.org/10.1038/sj.bjc.6603072" @default.
• W2004703251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361252" @default.
• W2004703251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16570038" @default.
• W2004703251 hasPublicationYear "2006" @default.
• W2004703251 type Work @default.
• W2004703251 sameAs 2004703251 @default.
• W2004703251 citedByCount "56" @default.
• W2004703251 countsByYear W20047032512012 @default.
• W2004703251 countsByYear W20047032512013 @default.
• W2004703251 countsByYear W20047032512015 @default.
• W2004703251 countsByYear W20047032512016 @default.
• W2004703251 countsByYear W20047032512018 @default.
• W2004703251 countsByYear W20047032512019 @default.
• W2004703251 countsByYear W20047032512020 @default.
• W2004703251 countsByYear W20047032512021 @default.
• W2004703251 countsByYear W20047032512022 @default.
• W2004703251 crossrefType "journal-article" @default.
• W2004703251 hasAuthorship W2004703251A5000738181 @default.
• W2004703251 hasAuthorship W2004703251A5008014743 @default.
• W2004703251 hasAuthorship W2004703251A5018138745 @default.
• W2004703251 hasAuthorship W2004703251A5026785555 @default.
• W2004703251 hasAuthorship W2004703251A5034002948 @default.
• W2004703251 hasAuthorship W2004703251A5054141760 @default.
• W2004703251 hasAuthorship W2004703251A5065402521 @default.
• W2004703251 hasAuthorship W2004703251A5072306746 @default.
• W2004703251 hasBestOaLocation W20047032511 @default.
• W2004703251 hasConcept C121608353 @default.
• W2004703251 hasConcept C126322002 @default.
• W2004703251 hasConcept C2777334693 @default.
• W2004703251 hasConcept C2780259306 @default.
• W2004703251 hasConcept C29730261 @default.
• W2004703251 hasConcept C31760486 @default.
• W2004703251 hasConcept C44249647 @default.
• W2004703251 hasConcept C526805850 @default.
• W2004703251 hasConcept C71924100 @default.
• W2004703251 hasConcept C90924648 @default.
• W2004703251 hasConceptScore W2004703251C121608353 @default.
• W2004703251 hasConceptScore W2004703251C126322002 @default.
• W2004703251 hasConceptScore W2004703251C2777334693 @default.
• W2004703251 hasConceptScore W2004703251C2780259306 @default.
• W2004703251 hasConceptScore W2004703251C29730261 @default.
• W2004703251 hasConceptScore W2004703251C31760486 @default.
• W2004703251 hasConceptScore W2004703251C44249647 @default.
• W2004703251 hasConceptScore W2004703251C526805850 @default.
• W2004703251 hasConceptScore W2004703251C71924100 @default.
• W2004703251 hasConceptScore W2004703251C90924648 @default.
• W2004703251 hasIssue "8" @default.
• W2004703251 hasLocation W20047032511 @default.
• W2004703251 hasLocation W20047032512 @default.
• W2004703251 hasLocation W20047032513 @default.
• W2004703251 hasLocation W20047032514 @default.
• W2004703251 hasOpenAccess W2004703251 @default.
• W2004703251 hasPrimaryLocation W20047032511 @default.

• next